Discovery and development of N-cadherin antagonists

被引：27

作者：

Blaschuk, Orest W. ^{[1
,2
]}

机构：

[1] McGill Univ, Dept Surg, Div Urol, Montreal, PQ H3A 2T5, Canada

[2] Royal Victoria Hosp, Urol Res Labs, Montreal, PQ H3A 1A1, Canada

来源：

CELL AND TISSUE RESEARCH | 2012年 / 348卷 / 02期

关键词：

N-cadherin; Angiogenesis; Cancer; ADH-1; Endothelial cells; CELL-ADHESION; NEURITE OUTGROWTH; MIGRATION; GROWTH; ADH-1; IDENTIFICATION; ANGIOGENESIS; MECHANISMS; INDUCTION; PEPTIDE;

D O I：

10.1007/s00441-011-1320-5

中图分类号：

Q2 [细胞生物学];

学科分类号：

071013 [干细胞生物学];

摘要：

This article describes over 20 years of research on antagonists of the cell adhesion molecule, N-cadherin. Four types of antagonists are discussed: synthetic linear peptides, synthetic cyclic peptides, non-peptidyl peptidomimetics of the disulfide linked cyclic peptide N-Ac-CHAVC-NH2 and monoclonal antibodies directed against the N-cadherin ectodomain. The biological activities of these antagonists are also discussed. In particular, the ability of N-cadherin antagonists to act as anti-cancer drugs is considered.

引用

收藏

页码：309 / 313

页数：5

相关论文

共 40 条

[1]

Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment [J].

Augustine, Christina K. ;

Yoshimoto, Yasunori ;

Gupta, Mukur ;

Zipfel, Patricia A. ;

Selim, M. Angelica ;

Febbo, Phillip ;

Pendergast, Ann Marie ;

Peters, William P. ;

Tyler, Douglas S. .

CANCER RESEARCH, 2008, 68 (10) :3777-3784

[2]

Cellular abnormalities of blood vessels as targets in cancer [J].

Baluk, P ;

Hashizume, H ;

McDonald, DM .

CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (01) :102-111

[3]

A Phase 1 Study of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Locally Advanced In-Transit Malignant Melanoma [J].

Beasley, Georgia M. ;

McMahon, Nicole ;

Sanders, Gretchen ;

Augustine, Christina K. ;

Selim, Maria A. ;

Peterson, Bercedis ;

Norris, Robin ;

Peters, William P. ;

Ross, Merrick I. ;

Tyler, Douglas S. .

CANCER, 2009, 115 (20) :4766-4774

[4]

Blaschuk O.W., 2000, U.S. Patent, Patent No. [6,031,072, 6031072]

[5]

Blaschuk O.W., 2003, U.S. Patent, Patent No. [6,610,821, 6610821]

[6]

Cadherins as novel targets for anti-cancer therapy [J].

Blaschuk, Orest W. ;

Devemy, Emmanuelle .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 625 (1-3) :195-198

[7]

IDENTIFICATION OF A CADHERIN CELL-ADHESION RECOGNITION SEQUENCE [J].

BLASCHUK, OW ;

SULLIVAN, R ;

DAVID, S ;

POULIOT, Y .

DEVELOPMENTAL BIOLOGY, 1990, 139 (01) :227-229

[8]

Cadherin Switching and Bladder Cancer [J].

Bryan, Richard T. ;

Tselepis, Chris .

JOURNAL OF UROLOGY, 2010, 184 (02) :423-431

[9]

Identification of novel N-cadherin antagonist [J].

Devemy, Emmanuelle ;

Blaschuk, Orest W. .

PEPTIDES, 2008, 29 (11) :1853-1861

[10]

NEURITE OUTGROWTH IN RESPONSE TO TRANSFECTED N-CAM AND N-CADHERIN REVEALS FUNDAMENTAL DIFFERENCES IN NEURONAL RESPONSIVENESS TO CAMS [J].

DOHERTY, P ;

ROWETT, LH ;

MOORE, SE ;

MANN, DA ;

WALSH, FS .

NEURON, 1991, 6 (02) :247-258

← 1 2 3 4 →